Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals & M&A

Set Alert for Deals & M&A

Torrent Acquires Chronic Brands From Dr. Reddy’s, Folds Up US Liquids Business

Torrent is recalibrating strategy with the addition of chronic therapies from Dr. Reddy’s while it folds up an unsustainable liquids business in US. The latter resulted in the company reporting a Q4 loss but a timely bonus share issue propped up investor sentiment.

Commercial Deals

Deal Watch: Innoviva To Buy The Rest Of Entasis For Enterprise Value Of $113m

Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.

Deal Watch Business Strategies

CureVac Takes Another Shot At mRNA Vaccines, Expands Cancer Work

Its first COVID-19 vaccine failed last year, but fueled by payments from the EU, Germany and GSK, CureVac is trying again with two further versions of its mRNA platform.

Clinical Trials Commercial

High Hopes For Heidelberg Pharma With Huadong Onboard

CEO Jan Schmidt-Brand tells Scrip that with another reliable long-term investor on the team alongside major shareholder Dievini, Heidelberg is well positioned to advance its amanitin-targeted antibody-drug conjugate candidates.

Companies Cancer

Etrasimod Results Justify Pfizer’s Leap Of Faith In Arena Buyout

Detailed data presented at Digestive Disease Week show competitive efficacy in ulcerative colitis and a potential best-in-class safety profile for the S1P receptor modulator Pfizer acquired earlier this year. 

Clinical Trials Gastrointestinal

Vertex Spots Potential Bargain Of $60m Entry Into Complement Regulation

Vertex has acquired the full assets to a promising protease-based drug platform from Catalyst, broadening its R&D base once again.

Deals Ophthalmic

Zymeworks Rejects ‘Opportunistic’ Investor Takeover Bid

Activist investor All Blue wants to mount a takeover, but the biotech’s board is holding out for encouraging pipeline news to help fight off the bid.

Companies Commercial

Stock Watch: Biotech’s Commercial Laggards Drag On Sector

Some commercial-stage biotechnology companies blame the pandemic for their declining sales and continued losses. While an acquisition by a bigger company might once have been an aspiration, further fundraisings seem to be the more likely outcome.

Stock Watch Commercial

Finance Watch: CARB-X Refills Coffers To Help Biopharmas Fight Resistant Bacteria

Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round. 

Financing Innovation

Bayer Shuffles Atara’s CAR-Ts Out Of Its Cell Therapy Deck

Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.

Companies Deals

Agios CEO Fouse On Building A Sustainable Business Model

In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.

Business Strategies Companies

Orphazyme’s Sorry Story Ends In Fire Sale

While Orphazyme's attempts to get approval for arimoclomol failed miserably, new owner KemPharm is confident it can get the oral heat shock protein amplifier across the regulatory finishing line for Niemann-Pick disease type C.

M & A Rare Diseases
UsernamePublicRestriction

Register